Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To explore the evidence for adopting a "treatable traits" approach to asthma management.
Data Sources: PubMed, Medline, and Google Scholar.
Study Selections: The above-mentioned databases were searched for randomized, controlled phase III or IV trials of adults containing the word "asthma" in the title published in the previous 10 years and for all articles containing the title words "treatable AND trait(s)," "asthma AND biomarker(s) OR smoking OR obesity OR laryngeal OR management" published within the previous 5 years. Articles were excluded if they were not published in English. Our search identified 257 articles for consideration. We also manually searched the reference lists of studies identified and searched the websites of the British Thoracic Society, European Respiratory Society, National Institute for Health and Care Excellence, and Global Initiative for Asthma for specific guidance related to asthma management.
Results: The "treatable traits" are described within 3 domains of pulmonary, extrapulmonary, or behavioral and lifestyle traits. We consider whether treatment should be targeted toward these traits where they are present in asthma patients, based on currently available evidence, rather than increasing treatment in response to symptoms in line with current step-up, step-down asthma management guidelines.
Conclusion: We advocate that a treatable traits approach should be applied more broadly to the assessment and management of inadequately controlled asthma, rather than a step-up, step-down approach based on patient symptoms. This approach should be focused on the 2 treatable pulmonary traits of T2 inflammation and airflow obstruction along with smoking cessation, in the first instance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anai.2022.02.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry.
Respir Med
September 2025
Centre of Excellence in Treatable Traits, College of Health, Medicine and Wellbeing, University of Newcastle, New Lambton Heights, NSW, Australia; Asthma and Breathing Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; Department of Respiratory and Sleep Medici
Background: The benefits of oral corticosteroid (OCS) stewardship approaches -including monoclonal antibody treatments for severe asthma- on reducing toxic OCS exposure and related comorbidities such as depression and anxiety require real-world evaluation.
Methods: This real-world observational study investigated OCS exposure and associated complications over 24 months in patients enrolled in the Australian Mepolizumab Registry (n=412).
Results: Patients were median age 59 years, 58% were female.
Emerging Therapeutics in COPD: Mapping Innovation to Treatable Traits.
Lung
September 2025
Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous condition characterized by diverse clinical phenotypes and underlying pathobiological mechanisms. Traditional "one-size-fits-all" management strategies have limited effectiveness in addressing this heterogeneity. The Treatable Traits (TTs) approach represents a precision medicine paradigm that targets specific, identifiable, and modifiable traits in individual patients, regardless of diagnostic labels.
View Article and Find Full Text PDFComorbidities as treatable traits of chronic airway diseases.
Respir Med
August 2025
Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
Chronic airway diseases, including asthma, chronic obstructive pulmonary disease, and bronchiectasis, are increasingly recognized as heterogeneous conditions influenced not only by airway pathology but also by a wide range of extrapulmonary and behavioral comorbidities. The treatable traits (TT) model, as it has emerged in recent medical literature, offers a precision medicine framework that redefines comorbidities as clinically relevant, identifiable, and modifiable traits. This paradigm shifts the focus from conventional disease labels to a multidimensional approach that considers the individual's unique constellation of pulmonary, extrapulmonary, and psychosocial features.
View Article and Find Full Text PDFTreatable traits in chronic cough: a prospective evaluation for predicting cough persistence.
ERJ Open Res
July 2025
Department of Allergy and Clinical Immunology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Background: The concept of treatable traits has been proposed for managing chronic cough; however, evidence supporting its clinical utility remains limited. This study investigated the relationship between baseline traits and cough persistence in a prospective registry of patients with chronic cough.
Methods: We analysed data from 426 patients with chronic cough enrolled in the Korean Chronic Cough Registry.
Identifying Treatable Traits of Patients with Asthma Prescribed an ICS/LABA: A Descriptive Analytic Database Study in England.
Adv Ther
August 2025
GSK, Dubai, UAE.
Introduction: We aimed to understand predictors of moderate-to-severe asthma exacerbations and high short-acting β-agonist (SABA) use in adults with asthma newly initiating single-inhaler twice-daily inhaled corticosteroids/long-acting β-agonists (ICS/LABAs) in England.
Methods: This non-interventional, longitudinal, retrospective study used medical record data (Clinical Practice Research Datalink Aurum; Hospital Episode Statistics) in England. Eligible patients with diagnosed asthma were ≥ 18 years old 12 months before the first observed single-inhaler twice-daily ICS/LABA prescription date (December 1, 2017-March 31, 2019).